Abstract
Background
A recent prospective randomized trial demonstrated that prophylactic pasireotide reduces the incidence of pancreatic complications (PC) after resection. This secondary analysis aimed to describe quality of life (QoL) before and after resection, to characterize the impact of PC on QoL, and to assess whether pasireotide improves QoL.
Methods
A randomized, double-blind, placebo-controlled trial of preoperative pasireotide in patients undergoing pancreatectomy was conducted. Participants completed the European Organization for Research and Treatment of Cancer (EORTC) C30 and PAN26 modules preoperatively and on postoperative days 14 and 60. Scores were compared using t tests. The percentage of patients with clinically important worsening (a decline ≥0.5 times the baseline standard deviation) was reported.
Results
All questionnaires were completed by 87 % (260/300) of the patients. No major differences were observed between the pasireotide and placebo groups. Therefore, the data were pooled for further analyses. A significant worsening of function at 14 days was detected on all the PAN26 and C30 function scales except hepatic and emotional functioning (EF), and on all the C30 symptom scales. More than 75 % of the patients experienced clinically important worsening of fatigue, pain, and role functioning. Most effects persisted at 60 days, with the 60-day EF significantly better than at baseline (p = 0.03). PC were associated with worse outcomes on most function scales.
Conclusions
During the 14 days after resection, patients can be expected to have a significant decline in QoL. Many symptoms abate by 60 days, and EF improves. PC were associated with impaired QoL in several domains. Although pasireotide effectively reduced PC, its effect did not appear to translate to improved QoL in this sample of 300 patients.
Similar content being viewed by others
References
Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg. 1995;221:721–31; discussion 721–31
Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996;83:625–31.
Numico G, Longo V, Courthod G, Silvestris N. Cancer survivorship: long-term side effects of anticancer treatments of gastrointestinal cancer. Curr Opin Oncol. 2015;27:351–7.
Spalding NJ. Reducing anxiety by preoperative education: make the future familiar. Occup Ther Int. 2003;10:278–93.
Wilson CJ, Mitchelson AJ, Tzeng TH, et al. Caring for the surgically anxious patient: a review of the interventions and a guide to optimizing surgical outcomes. Am J Surg. 2015. doi: 10.1016/j.amjsurg.2015.03.023
Fitzsimmons D, Johnson CD, George S, et al. Development of a disease-specific quality-of-life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer Oxford Engl 1990. 1999;35:939–41.
EORTC. Modules in Development and Available for Use. http://groups.eortc.be/qol/modules-development-and-available-use. Accessed 1 June 2015
Keck T, Wellner UF, Bahra M, et al. Pancreatogastrostomy versus pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): perioperative and long-term results of a multicenter randomized controlled trial. Ann Surg. 2015. doi: 10.1097/SLA.0000000000001240
Moningi S, Walker AJ, Hsu CC, et al. Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic. J Oncol Pract/Am Soc Clin Oncol. 2015;11:e216–21.
Allen PJ, Gönen M, Brennan MF, et al. Pasireotide for postoperative pancreatic fistula. N Engl J Med. 2014;370:2014–22.
Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: EORTC Publications; 2001.
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–92.
Crippa S, Dominguez I, Rodriguez JR, et al. Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg. 2008;12:783–93; discussion 793–94
Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, Obertop H, de Haes JC, Gouma DJ. Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg. 2005;92:471–7
Schniewind B, Bestmann B, Henne-Bruns D, Faendrich F, Kremer B, Kuechler T. Quality of life after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head. Br J Surg. 2006;93:1099–107.
McNulty J, Khera N. Financial hardship: an unwanted consequence of cancer treatment. Curr Hematol Malig Rep. 2015. doi: 10.1007/s11899-015-0266-1
Shaw CM, O’Hanlon DM, McEntee GP. Long-term quality of life following pancreaticoduodenectomy. Hepatogastroenterology. 2005;52:927–32.
Acknowledgments
This work was supported in part by Cancer Center core grant P30 CA008748. The core grant provides funding to institutional cores such as Biostatistics, which was used in this study. The research was funded by Novartis.
Disclosure
Dr Peter J. Allen has worked in a consulting/advisory role for Sanofi and received research funding from Novartis.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Eaton, A.A., Gonen, M., Karanicolas, P. et al. Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial. Ann Surg Oncol 23, 2137–2145 (2016). https://doi.org/10.1245/s10434-015-5077-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-015-5077-z